Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788835 | 0.86 | NLRP3 (0.31) | — | |
| SCHEMBL8485861 | 0.74 | ALDH1A1 (0.31) | ALDH1A1LMNATP53 | |
| SCHEMBL9724591 | 0.74 | POLB (0.37) | ALDH1A1 | |
| SCHEMBL11251469 | 0.73 | PMP22 (0.38) | ALDH1A1LMNATP53 | |
| SCHEMBL1045911 | 0.70 | PTGS1 (0.36) | LMNA | |
| SCHEMBL1665110 | 0.69 | — | — | |
| SCHEMBL5635440 | 0.69 | LMNA (0.39) | ALDH1A1LMNATP53 | |
| SCHEMBL25333023 | 0.69 | ALDH1A1 (0.61) | ALDH1A1LMNATP53 | |
| SCHEMBL148081 | 0.68 | — | — | |
| SCHEMBL18280923 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115626-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11801273-B2 | Compositions and methods to increase production of isothiocyanates | CHURCH & DWIGHT CO., INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023133494-A2 | OIL-BASED ISOTHIOCYANATE PRODUCTS AND PROCESSES FOR PREPARING OIL-BASED ISOTHIOCYANATE PRODUCTS | BRASSICA PROTECTION PRODUCTS LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2022140409-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193152-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160038485-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | TALALAY, PAUL | 2016-02-11 | — | — | US | disclosed |
| US-8927007-B2 | Formulations for treatment with glucosinolates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-06 | — | — | US | disclosed |
| EP-2616883-A1 | ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE | Ricoh Company Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| EP-2616061-A2 | FORMULATIONS FOR TREATMENT WITH GLUCOSINOLATE | Brassica Protection Products LLC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130164365-A1 | FORMULATIONS FOR TREATMENT WITH GLUCOSINOLATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-27 | — | — | US | disclosed |
| WO-2012036295-A1 | ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE | RICOH COMPANY, LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037193-A2 | FORMULATIONS FOR TREATMENT WITH GLUCOSINOLATE | BRASSICA PROTECTION PRODUCTS LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20100015085-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS | JOHNS HOPKINS UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | ALDH1A1 658/4885LMNA 2406/4885TP53 277/4885 |
| US-20160038485-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | ALDH1A1 658/4885LMNA 2406/4885TP53 277/4885 |
| US-20100015085-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS | PTGES2, PTGS2, PPARG | ALDH1A1 1180/4885LMNA 2819/4885TP53 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.